MANE · Veradermics

The thesis

Veradermics' extended-release oral minoxidil tablet, VDPHL01, has finished its male trials with clean 12-month safety, and the company's cash is guided to last into 2030. The shares now turn on when the company sets a date to submit its new drug application (NDA) for approval. The rating is Medium because the clinical risk in men is largely behind the company, while the filing date is still unstated. The next scheduled venue for that date is the company's presentation at the Jefferies Global Healthcare Conference in London on 19 November 2026.

The company's third-quarter 8-K exhibit, released 10 November 2026, shows cash, cash equivalents and marketable securities of $798.4 million on 30 September 2026 and a quarterly net loss of $21.0 million. The company said that cash funds operations "into 2030 through multiple Phase 3 readouts and potential commercial launch of VDPHL01." The release named no filing date.

The shares closed at $135.29 on 12 November 2026, a session in which MarketBeat reported a 13.3% intraday fall and identified no specific catalyst. The 3-month change is 20.0%, and the close sits above the 50-day moving average of $121.59, per adjusted daily closes. The price already reflects positive male trials but no approval timetable: MarketBeat's average analyst target was $174.57 on 12 November 2026, across seven Buy, one Hold and one Sell rating.

Bullish and bearish views on Veradermics, Incorporated

The bull case on Veradermics, Incorporated (MANE), in brief: hair counts kept rising through Month 12. The bear case: the filing date is still unstated.

Bull case

• Hair counts kept rising through Month 12. In Study '302', non-vellus hair count rose 43.9 hairs/cm² on 8.5mg twice daily and 29.7 on once daily at Month 12, per the company's 9 November 2026 release. The twice-daily figure is the highest the Phase 3 program has reported.
• Long-term safety came back clean. The 9 November 2026 release reported no treatment-related serious adverse events, no cardiac adverse events of special interest and no adverse-event discontinuations between Months 6 and 12 in 519 men.
• Cash covers the path to launch. Cash and marketable securities were $798.4 million on 30 September 2026 against a third-quarter net loss of $21.0 million, per the 10 November 2026 release. That release mentioned no new share offering or at-the-market sales program.
• Analysts raised targets after the data. Citigroup kept a Buy rating and raised its target to $175 from $160 on 10 November 2026. Leerink Partners raised its target to $150 from $135 on 9 November 2026, per Investing.com and MarketBeat.
• The women's study is the next readout. Study '306' in female pattern hair loss finished enrolment in August 2026, and the company said on 10 November 2026 that topline data remain on track for the first half of 2027.

Bear case

• The filing date is still unstated. Neither the 9 November 2026 trial release nor the 10 November 2026 quarterly release gave an NDA submission date. With the male clinical work complete, the absence of a date is the main open question.
• The 12-month side-effect rates are missing. The 12-month release gave no rates for excess body hair growth or leg and foot swelling. In Study '304', excess hair growth reached 9.0% of twice-daily patients and peripheral edema 4.5%, per the 19 October 2026 release.
• Costs are rising before any revenue. General and administrative expense rose to $12.7 million in the third quarter from $2.3 million a year earlier, driven by personnel, stock-based compensation and commercial-readiness costs, per the 10 November 2026 release. The company has no product revenue.
• Early holders sold after the lock-up. SEC Form 4 filings show director Montanova Capital selling 750,000 shares at $107.25 on 19 August 2026 and director John Childs selling 100,000 shares at an average $107.12 on 12 August 2026. Connecticut Innovations reported record quarterly venture proceeds of $51.4 million on 5 November 2026, largely from the Veradermics IPO.
• The shares can reverse without news. MarketBeat reported a 13.3% intraday fall on 12 November 2026 with no identified catalyst, two sessions after the quarterly report and the Citigroup target increase.

Price setup

The last close was $135.29 on 12 November 2026, per adjusted daily closes. The 50-day moving average stood at $121.59 on the same date, and the 3-month change is 20.0%. The close remains above the 5 November 2026 close that preceded the 12-month Study '302' release, so the shares still hold part of the gain from that readout.

The 12 November 2026 decline came on mid-session volume of 553,990 shares against an average of 639,178, per MarketBeat. Leerink's $150 target and Citigroup's $175 target both sit above the last close.

SEC Form 4 filings show no insider sales dated after 19 August 2026. The open-market sales followed the 3 August 2026 lock-up expiry and were clustered between $106 and $112 a share; the chief executive's 67,500-share sale on 17 August 2026 was made under a Rule 10b5-1 trading plan.

Catalysts ahead

• 19 November 2026: Management presentation at the Jefferies Global Healthcare Conference in London, 8:30 a.m. GMT, with a live webcast. The first scheduled public appearance since the Month-12 data and the quarterly report, and a venue where management could give an NDA submission timeline.
• Not yet announced: NDA submission announcement for VDPHL01 in male pattern hair loss; no date given as of 10 November 2026. The male trials are complete, so a dated submission moves the case from timing risk to a regulatory review schedule.
• 1H 2027 (est.): Study '306' Phase 2/3 topline in female pattern hair loss (556 women, 4.5mg). A positive result would widen the commercial market without changing the male approval path.
• ~30 March 2027 (est.): Fourth-quarter and full-year 2026 results. Next scheduled update on cash against the into-2030 guidance and the likeliest venue for a filing timeline if none comes sooner.

What would change the view

A daily close below $128, under the $128.60 close of 5 November 2026 that preceded the 12-month release. The case also ends if the company sells new equity before an NDA filing despite its into-2030 cash guidance, or places the filing in late 2027 or later.

The risks this note tracks, each with what would confirm it:

• The NDA filing timeline slips or stays vague after the clinical program is complete. Confirmed by: no submission date by the fourth-quarter report, or company language pointing to a submission in late 2027 or later.
• The company raises equity after the trial success despite its cash guidance. Confirmed by: a new public offering or at-the-market program announced before an NDA submission.
• Fuller 12-month data show side-effect rates that weaken the label or patient uptake. Confirmed by: published 12-month hypertrichosis or peripheral edema rates well above the Study '304' six-month figures of 9.0% and 4.5% on twice-daily dosing.
• Early holders and insiders resume selling into strength. Confirmed by: new director or major-holder sales on SEC Form 4 filings dated after 12 November 2026.
• Cheap off-label generic oral minoxidil caps pricing for a branded tablet. Confirmed by: management framing VDPHL01 as cash-pay at a modest premium, or telehealth providers launching competing extended-release formulations.

What it trades with

The shares trade on company-specific trial and regulatory news. Benzinga reported a gain of about 10% on the 19 October 2026 Study '304' readout, and the shares rose again around the 9 November 2026 Month-12 release before falling 13.3% intraday on 12 November 2026. Sector read-across comes mainly from the treatment the tablet competes with: cheap off-label generic oral minoxidil sold through telehealth providers, where pricing or new extended-release versions would bear directly on VDPHL01's commercial case.